Study On Correlation Between The Expressions Of ER,the Role Of Relative Factors On The Effect Of TAC Neoadjuvant Chemotherapy For The Patients With Breast Cancer

Objective:To investigate the breast cancer patients with ER, PR, HER-2, Ki-67andP53expression and neoadjuvant chemotherapy (Neoadjuvant chemotherapy, NCT)efficacy of the relationship, looking before chemotherapy effectively predict breast cancerto neoadjuvant chemotherapy biologyindicators.Methods:79patients with breast cancer before surgery underwent the hollow needleaspiration biopsy by immunohistochemistry (Immunohistochemistry, IHC) detectionpreoperative and postoperative ER, PR, HER-2, Ki-67and P53expression andobservation TAC neoadjuvant chemotherapy chemotherapy effects.Results:79patients with breast cancer after neoadjuvant chemotherapy after2-6cycles,with a total effective rate of26.6%(21/79) CR and7patients (8.9%), pCR3patients(3.8%), PR,14cases (17.7%), SD in56patients (70.9%), and PD in2patients (2.5%); ER,PR, P53negative expression rate was54.4%，50.6%and50.6%; the HER-2over-expression was36.7%, the expression of Ki-67≥14%was48.1%. ER-negativegroup with ER-positive group, the PR negative group and PR-positive groupchemotherapy efficacy difference was statistically significant (P<0.05),HER-2overexpression group and the non-overexpression group, Ki-67≥14%and Ki-67<14%,P53negative group and positive group chemotherapy efficacy difference was notstatistically significant (P>0.05). Conclusions:ER-negative, PR-negative breast cancerpatients on chemotherapy may be more sensitive to possible, ER, PR neoadjuvantchemotherapy sensitivity predictors.